sacubitril and valsartan

FDA Drug Profile — sacubitril and valsartan

sacubitril and valsartan is listed in the FDA National Drug Code directory with 24 NDC codes, marketed under brand name including sacubitril and valsartan. Available dosage forms: tablet, film coated, tablet.

Drug details

Generic Name
sacubitril and valsartan
Brand Names
sacubitril and valsartan
Application Number
ANDA213682
Sponsor
Alembic Pharmaceuticals Limited
NDC Codes
24
Dosage Forms
TABLET, FILM COATED, TABLET
Routes
ORAL
Active Ingredients
SACUBITRIL, VALSARTAN

Indications and Usage

1 INDICATIONS AND USAGE ENTRESTO is a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. ENTRESTO reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure ENTRESTO is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1)] . 1.2 Pediatric Heart Failure ENTRESTO is indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. ENTRESTO reduces NT-proBNP and is expected to improve cardiovascular outcomes.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.